Immune checkpoint receptors in autoimmunity

Curr Opin Immunol. 2023 Feb:80:102283. doi: 10.1016/j.coi.2023.102283. Epub 2023 Jan 28.

Abstract

Immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin and ITIM domain (TIGIT) have distinct and overlapping inhibitory functions that regulate Tcell activation, differentiation, and function. These inhibitory receptors also mediate tolerance, and dysregulation of these receptors can result in a breach of tolerance and the development of autoimmune syndromes. Similarly, antibody blockade of immune checkpoint receptors or their ligands for cancer immunotherapy may trigger a spectrum of organ inflammation that resembles autoimmunity, termed immune-related adverse events (irAE). In this review, we discuss recent advances in the regulation of autoimmunity by immune checkpoint receptors. We highlight coordinated gene expression programs linking checkpoint receptors, heterogeneity within autoreactive T-cell populations, parallels between irAE and autoimmunity, and bidirectional functional interactions between immune checkpoint receptors and their ligands.

Keywords: Autoimmunity; Checkpoint receptor ligand; Checkpoint receptors; Immune related adverse event (irAE); PD-1; PD-L1; T cell tolerance.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmunity
  • CTLA-4 Antigen
  • Humans
  • Immune System Diseases* / metabolism
  • Immunotherapy
  • Ligands
  • Neoplasms*
  • Receptors, Immunologic / metabolism
  • T-Lymphocytes

Substances

  • Ligands
  • CTLA-4 Antigen
  • Receptors, Immunologic